Financial Instruments

12 Months Ended

Dec. 31, 2013

2. Financial Instruments

A summary of financial instruments measured at fair value is as follows (in thousands):



December 31, 2013	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	5,349	$	--	$	--	$	5,349
Certificates of deposit		749		--		--		749
Restricted securities:
Money market funds		350		--		--		350
Total assets	$	6,448	$	--	$	--	$	6,448
Long-term liabilities:
Contingent consideration	$	--	$	--	$	(1,884)	$	(1,884)
Total liabilities	$	--	$	--	$	(1,884)	$	(1,884)



December 31, 2012	Level 1		Level 2		Level 3		Total
Cash equivalents:
Money market funds	$	1,319	$	--	$	--	$	1,319
Restricted securities:
Money market funds		323		--		--		323
Total assets	$	1,642	$	--	$	--	$	1,642
Long-term liabilities:
Contingent consideration	$	--	$	--	$	(1,912)	$	(1,912)
Total liabilities	$	--	$	--	$	(1,912)	$	(1,912)

The Company used prices quoted from its investment management companies to determine the Level 1 valuation of its investments in money market funds, certificates of deposit, and securities. The Company changed the presentation of its December 31, 2012 money market funds to Level 1 from Level 2, consistent with its current year presentation. The Company recorded contingent consideration liability, classified as Level 3, as a result of its acquisition of Hemosphere in May 2012. Refer to Note 4 for further discussion of the Level 3 contingent consideration liability. Changes in fair value of Level 3 liabilities are listed below (in thousands):



	Contingent Consideration
Balance as of December 31, 2012	$	1,912
Gain on remeasurement of contingent consideration		(28)
Balance as of December 31, 2013	$	1,884

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References+ Details